The paradox of response and survival in cancer therapeutics

被引:112
作者
Huff, CA [1 ]
Matsui, W [1 ]
Smith, BD [1 ]
Jones, RJ [1 ]
机构
[1] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
关键词
D O I
10.1182/blood-2005-06-2517
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although most patients with cancer respond to therapy, few are cured. Moreover, objective clinical responses to treatment often do not even translate into substantial improvements in overall survival. For example, patients with indolent lymphoma who achieved a complete remission with conventional-dose therapies in the prerituximab era did not experience a survival advantage over similar patients treated with a '' watch and wait '' approach. Several studies have also shown that neither the magnitude nor the kinetics of clinical response has an impact on survival in multiple myeloma. Recent data suggesting many malignancies arise from a rare population of cells that exclusively maintains the ability to self-renew and sustains the tumor (ie, '' cancer stem cells '') may help explain this paradox that response and survival are not always linked. Therapies that successfully eliminate the differentiated cancer cells characterizing the tumor may be ineffective against rare, biologically distinct cancer stem cells. New methods for assessing treatment efficacy must also be developed, as traditional response criteria measure tumor bulk and may not reflect changes in rare cancer stem cell populations. In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches.
引用
收藏
页码:431 / 434
页数:4
相关论文
共 46 条
[1]   Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer [J].
Abratt, RP ;
Brune, D ;
Dirnopoulos, MA ;
Kliment, J ;
Breza, J ;
Selvaggi, FP ;
Beuzeboc, P ;
Demkow, T ;
Oudard, S .
ANNALS OF ONCOLOGY, 2004, 15 (11) :1613-1621
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]   Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors [J].
Angstreich, GR ;
Matsui, W ;
Huff, CA ;
Vala, MS ;
Barber, J ;
Hawkins, AL ;
Griffin, CA ;
Smith, GBD ;
Jones, RJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) :373-381
[4]  
BEDI A, 1993, BLOOD, V81, P2898
[5]   IMPACT OF RESPONSE TO TREATMENT ON SURVIVAL IN MULTIPLE-MYELOMA - RESULTS IN A SERIES OF 243 PATIENTS [J].
BLADE, J ;
LOPEZGUILLERMO, A ;
BOSCH, F ;
CERVANTES, F ;
REVERTER, JC ;
MONTSERRAT, E ;
ROZMAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) :117-121
[6]   Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR- [J].
Blair, A ;
Hogge, DE ;
Sutherland, HJ .
BLOOD, 1998, 92 (11) :4325-4335
[7]   Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].
Bonifazi, F ;
de Vivo, A ;
Rosti, G ;
Guilhot, F ;
Guilhot, J ;
Trabacchi, E ;
Hehlmann, R ;
Hochhaus, A ;
Shepherd, PCA ;
Steegmann, JL ;
Kluin-Nelemans, HC ;
Thaler, J ;
Simonsson, B ;
Louwagie, A ;
Reiffers, J ;
Mahon, FX ;
Montefusco, E ;
Alimena, G ;
Hasford, J ;
Richards, S ;
Saglio, G ;
Testoni, N ;
Martinelli, G ;
Tura, S ;
Baccarani, M .
BLOOD, 2001, 98 (10) :3074-3081
[8]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[9]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[10]   Goals and objectives in the management of metastatic breast cancer [J].
Chung, CT ;
Carlson, RW .
ONCOLOGIST, 2003, 8 (06) :514-520